Study details
Enrolling now
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
Mclean Hospital
NCT IDNCT06477406ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 2.3 years
Ages
21+
Sex
Female only
Locations
1 site in MA
What this study is about
Researchers are testing whether a custom-formulated cannabinoid product helps with symptoms and biomarkers in women with endometriosis. The trial will last 854 days, and participants will receive either the cannabinoid product or a placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cannabidiol
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cannabidiol
Drug routes
oral (Oral Solution)
Endpoints
Primary: Visual Analog Scale (VAS)
Secondary: Beck Depression Inventory (BDI), VAS-IBS
Body systems
Reproductive Health